Latest Insider Transactions at Natera, Inc. (NTRA)
This section provides a real-time view of insider transactions for Natera, Inc. (NTRA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Natera, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Natera, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 04
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
3,070
-0.24%
|
$411,380
$134.09 P/Share
|
|
Apr 03
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
3,000
-0.81%
|
$417,000
$139.28 P/Share
|
|
Apr 01
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
3,000
-0.7%
|
$420,000
$140.79 P/Share
|
|
Apr 01
2025
|
Gail Boxer Marcus |
SELL
Open market or private sale
|
Direct |
4,000
-6.55%
|
$564,000
$141.14 P/Share
|
|
Apr 01
2025
|
Gail Boxer Marcus |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+13.38%
|
$64,000
$16.14 P/Share
|
|
Apr 01
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
15,898
-1.92%
|
$2,225,720
$140.74 P/Share
|
|
Mar 31
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
9,563
-2.16%
|
$1,319,694
$138.42 P/Share
|
|
Mar 31
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,562
-1.64%
|
$353,556
$138.39 P/Share
|
|
Mar 31
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,404
-0.31%
|
$193,752
$138.4 P/Share
|
|
Mar 28
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
18,750
+7.78%
|
-
|
|
Mar 28
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+7.41%
|
-
|
|
Mar 28
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+1.09%
|
-
|
|
Mar 28
2025
|
Monica Bertagnolli |
BUY
Grant, award, or other acquisition
|
Direct |
2,877
+50.0%
|
-
|
|
Mar 18
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
3,000
-1.75%
|
$435,000
$145.97 P/Share
|
|
Mar 18
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
2,700
-0.35%
|
$391,500
$145.86 P/Share
|
|
Mar 17
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
792
-0.55%
|
$116,424
$147.8 P/Share
|
|
Mar 17
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
6,702
-3.19%
|
$978,492
$146.03 P/Share
|
|
Mar 17
2025
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
795
-0.25%
|
$116,865
$147.8 P/Share
|
|
Mar 17
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
1,026
-0.35%
|
$150,822
$147.89 P/Share
|
|
Mar 17
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
928
-0.21%
|
$136,416
$147.89 P/Share
|
|
Mar 17
2025
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Direct |
1,127
-0.02%
|
$165,669
$147.8 P/Share
|
|
Mar 17
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
181
-0.07%
|
$26,426
$146.03 P/Share
|
|
Mar 14
2025
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Direct |
50,000
-0.42%
|
$7,350,000
$147.39 P/Share
|
|
Mar 12
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,032
+2.72%
|
-
|
|
Mar 12
2025
|
Gail Boxer Marcus |
SELL
Open market or private sale
|
Direct |
4,000
-8.19%
|
$588,000
$147.76 P/Share
|
|
Mar 12
2025
|
Gail Boxer Marcus |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+22.59%
|
$28,000
$7.86 P/Share
|
|
Mar 12
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
6,702
+3.09%
|
-
|
|
Mar 12
2025
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,040
+1.27%
|
-
|
|
Mar 12
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
BUY
Grant, award, or other acquisition
|
Direct |
2,040
+1.38%
|
-
|
|
Mar 12
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,740
+0.77%
|
-
|
|
Mar 12
2025
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
BUY
Grant, award, or other acquisition
|
Direct |
2,893
+0.12%
|
-
|
|
Mar 12
2025
|
Jonathan Sheena |
BUY
Grant, award, or other acquisition
|
Direct |
411
+0.16%
|
-
|
|
Mar 05
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
87,272
-6.77%
|
$12,479,896
$143.78 P/Share
|
|
Mar 05
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
6,000
-1.02%
|
$858,000
$143.56 P/Share
|
|
Feb 26
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
3,000
-0.68%
|
$477,000
$159.91 P/Share
|
|
Feb 26
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
2,700
-0.21%
|
$429,300
$159.19 P/Share
|
|
Feb 06
2025
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
663
-0.42%
|
$117,351
$177.77 P/Share
|
|
Feb 06
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
1,632
-1.08%
|
$288,864
$177.77 P/Share
|
|
Feb 05
2025
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,675
+1.06%
|
-
|
|
Feb 05
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
BUY
Grant, award, or other acquisition
|
Direct |
3,197
+1.05%
|
-
|
|
Feb 03
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
43,502
-10.87%
|
$7,656,352
$176.86 P/Share
|
|
Jan 31
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,286
-1.08%
|
$397,764
$174.83 P/Share
|
|
Jan 31
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
12,720
+10.0%
|
-
|
|
Jan 31
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
36,682
+11.21%
|
-
|
|
Jan 31
2025
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
11,832
+7.09%
|
-
|
|
Jan 31
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
BUY
Grant, award, or other acquisition
|
Direct |
12,720
+7.9%
|
-
|
|
Jan 31
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,353
+4.43%
|
-
|
|
Jan 31
2025
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
BUY
Grant, award, or other acquisition
|
Direct |
29,345
+1.2%
|
-
|
|
Jan 31
2025
|
Jonathan Sheena |
BUY
Grant, award, or other acquisition
|
Direct |
3,549
+1.33%
|
-
|
|
Jan 31
2025
|
Roy D. Baynes |
BUY
Grant, award, or other acquisition
|
Direct |
92
+0.58%
|
-
|